Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about finding a high-quality copper peptide powder for long-term hair growth, to be mixed with rosemary oil. It also suggests using finasteride for hair loss treatment.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The user is treating androgenetic alopecia with finasteride and discovered a folic acid deficiency. They are asking if curing the deficiency can worsen or improve their hair condition.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A user in their mid-30s experienced unexpected hairline regrowth after starting a new supplement stack, despite being on a regimen of finasteride, minoxidil, and Nizoral for over four years. The new supplements include Tongkat Ali, Fadogia Agrestis, Panax Red Ginseng, Vitamin B1, Vitamin D3, Zinc Picolinate, Magnesium Glycinate, Maca, and L-Citrulline.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

The user experienced hair shedding after starting testosterone replacement therapy (TRT) and is considering using DHT blockers like finasteride or dutasteride to address potential DHT-related hair loss. Low ferritin levels due to frequent blood donations may also contribute to hair issues, and the user is working on stabilizing iron levels.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Considering a hair transplant for diffuse thinning may harm existing follicles. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.

A user experiencing diffuse thinning at the hairline after 12 months on finasteride is considering adding minoxidil, dutasteride, or RU58841 to their treatment. Another user suggests adding minoxidil now, holding off on dutasteride, and shares personal side effects from RU58841.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

A user shared their hair transplant update, having received 4,300 grafts and choosing not to use medications like finasteride or minoxidil due to potential side effects and personal reasons. Many commenters expressed concern that without these medications, the user might experience further hair loss, suggesting that preventative treatments are important for maintaining transplant results.

Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.

The conversation discusses the effectiveness of combining Laminaria japonica and Cistanche tubulosa extracts for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

A user is treating their advanced hair loss with a regimen including topical finasteride, minoxidil, hydrocortisone, stem cell serum, peptide serum, multivitamins, he shou wu tea, derma pen, argan oil, and a derma roller. Replies suggest it's too early to judge progress and recommend staying consistent, with one suggesting oral minoxidil as an additional option.